Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Melanoma Res ; 32(3): 135-141, 2022 06 01.
Article in English | MEDLINE | ID: mdl-35377865

ABSTRACT

In the last decade, systemic therapies such as immune checkpoint inhibitors and BRAF-MEK inhibitors have improved the prognosis of high-risk and advanced melanoma. With improved survival, melanoma survivorship is increasingly important, particularly in patients who have a good prognosis or are diagnosed at a younger age. It is increasingly recognized that cancer and its treatment is associated with increased cardiovascular morbidity and mortality. Indeed, data from observational studies and meta-analyses of randomized controls trials in melanoma show that systemic therapies may be associated with cardiac toxicities, such as myocardial infarction, heart failure, myocarditis and stroke. Our review will discuss cardiovascular disease and risk factors in the context of melanoma and outline the importance of cardiovascular risk modification in this population.


Subject(s)
Cardiovascular Diseases , Melanoma , Skin Neoplasms , Cardiovascular Diseases/epidemiology , Humans , Melanoma/drug therapy , Melanoma/pathology , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Melanoma, Cutaneous Malignant
2.
J Drugs Dermatol ; 20(10): 1063-1071, 2021 Oct 01.
Article in English | MEDLINE | ID: mdl-34636525

ABSTRACT

While biological treatments for chronic plaque psoriasis should be administered continuously to maximize and maintain efficacy, interruptions in therapy may be necessary for a number of reasons. We reviewed the evidence from clinical trials on efficacy, safety and immunogenicity in clinical trials for approved biologic agents for chronic plaque psoriasis. A systematic search of three major medical databases was performed and a total of 35 articles were included into the analysis, including 13 controlled trials. Trials assessing continuous therapy against dosing as-needed therapy (including infliximab, etanercept and secukinumab) have demonstrated superior efficacy for continuous regimes. However, randomized withdrawal trials for etanercept, adalimumab, ixekizumab, brodalumab, guselkumab, risankizumab and tildrakizumab, showed no significant impact on skin clearance rates in patients who are interrupted once and then re-treated. With the possible exception of infliximab, temporary interruption in biologic therapy appears to be safe and most agents will regain efficacy after re-introduction. J Drugs Dermatol. 2021;20(10):1063-1071. doi:10.36849/JDD.5716.


Subject(s)
Psoriasis , Adalimumab/adverse effects , Biological Therapy , Etanercept/adverse effects , Humans , Infliximab , Psoriasis/diagnosis , Psoriasis/drug therapy , Treatment Outcome
3.
Australas J Dermatol ; 60(4): 315-317, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31232457

ABSTRACT

Great toenail malalignment is characterised by lateral deviation of the longitudinal axis of the nail plate with respect to the hallux, and is usually post-traumatic, iatrogenic or due to congenital malalignment of the great toenails. We present cases of great toenail malalignment with onset in adolescence or young adulthood without preceding nail surgery or acute trauma. We postulate that this may represent a late-onset presentation of congenital malalignment of the great toenails.


Subject(s)
Nails, Malformed/pathology , Toes , Adolescent , Adult , Child , Conservative Treatment , Female , Humans , Male , Nails, Malformed/therapy , Young Adult
4.
Thromb Res ; 138: 86-90, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26702484

ABSTRACT

BACKGROUND AND AIMS: Current clinical decision rules for pulmonary embolism are based on adult populations and have not been validated in children. The objective was to identify and evaluate clinical features for a first lifetime episode of pulmonary embolism in children presenting to the emergency department. MATERIALS AND METHODS: We present a case-control study of children (≤18years) presenting to the emergency department of the Royal Children's Hospital, Melbourne between November 2007 and February 2015. Children with radiologically proven pulmonary embolism formed the case group, whilst children in whom there was a clinical suspicion of pulmonary embolism but negative diagnostic imaging formed the control group. Charts, electronic medical and imaging records of both cases and controls were reviewed and analysed. RESULTS: There were a total of 50 patients in this study (11 cases and 39 controls). Current or recent (within three months) use of the oral contraceptive pill was the most significant risk factor in our study (odds ratio 14.667, 95% confidence interval 3.001-71.678, P<0.001). Most other features failed to discriminate between cases and controls, although there was a trend towards increased heart rate in cases. CONCLUSIONS: Pulmonary embolism is perhaps the most common presenting spontaneous venous thromboembolism in the community and teenage girls on the oral contraceptive pill are most at-risk amongst children. The clinical signs and symptoms are often non-specific. Additional larger studies are required to determine the significance and magnitude of potential clinical predictors identified in this study. This may lead to derivation of a paediatric-specific pre-test probability tool.


Subject(s)
Pulmonary Embolism/diagnosis , Pulmonary Embolism/epidemiology , Adolescent , Case-Control Studies , Child , Child, Preschool , Contraceptives, Oral, Combined/adverse effects , Emergency Service, Hospital , Female , Humans , Male , Pulmonary Artery/pathology , Pulmonary Embolism/chemically induced , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...